Cardiovascular disease is a group of disorders of the heart and blood vessels. Building on Sanofi’s legacy of more than 60 years of fighting cardiovascular disease, we deliver innovative therapeutic solutions for cardiovascular conditions to people at high risk for cardiac events (such as a heart attack) and who need additional treatment options beyond currently available medications.
Impacts of disease to Australian lives
Cardiovascular disease and associated risk factors significantly affect people’s quality of life and that of their families, and put a rising medical and economic burden on health systems worldwide.¹
Heart disease alone is the single leading cause of death in Australia: in 2017, almost 19,000 persons died from heart disease, with a further 1,250 deaths from ischaemic stroke. As a risk factor for both diseases, a large proportion of the burden associated with these diseases can be attributed to high cholesterol, also known as hypercholesterolaemia. There are an estimated 7.1 million Australians living with hypercholesterolaemia. This includes those individuals with measured high total cholesterol and those that self-reported as having high cholesterol. Reducing hypercholesterolaemia offers the potential for significant health and economic benefits.²
Our Heart is In It!
While people living with cardiovascular disease still face many challenges our team draws on our long global heritage and commitment to innovation to improve quality of life for all affected. Our people are passionate and committed to continue working together with health partners through disease awareness initiatives and healthcare solutions that can make a difference in the lives of people living with cardiovascular diseases.
Heart health research
Sanofi and the Heart Foundation are looking at why people with CVD appear to be more vulnerable to severe outcomes, and how we can better treat the cardiac complications of COVID-19.
- The Heart Foundation 2018 Cost of ACS to Governments, Individuals and Families accessed October 2020
- The Heart Foundation 2018 Economic burden of Hypercholesterolaemia accessed October 2020